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Abstract: This open-label, phase I first-in-human study (NCT01915576) of BAY 1125976, a highly
specific and potent allosteric inhibitor of AKT1/2, aimed to evaluate the safety, pharmacokinetics,
and maximum tolerated dose of BAY 1125976 in patients with advanced solid tumors. Oral dose
escalation was investigated with a continuous once daily (QD) treatment (21 days/cycle) and a twice
daily (BID) schedule. A dose expansion in 28 patients with hormone receptor-positive metastatic
breast cancer, including nine patients harboring the AKT1E17K mutation, was performed at the
recommended phase 2 dose (R2D) of 60 mg BID. Dose-limiting toxicities (Grades 3–4) were increased
in transaminases, γ-glutamyltransferase (γ-GT), and alkaline phosphatase in four patients in both
schedules and stomach pain in one patient. Of the 78 patients enrolled, one patient had a partial
response, 30 had stable disease, and 38 had progressive disease. The clinical benefit rate was 27.9%
among 43 patients treated at the R2D. AKT1E17K mutation status was not associated with tumor
response. Genetic analyses revealed additional mutations that could promote tumor cell growth
despite the inhibition of AKT1/2. BAY 1125976 was well tolerated and inhibited AKT1/2 signaling
but did not lead to radiologic or clinical tumor responses. Thus, the refinement of a selection of
biomarkers for AKT inhibitors is needed to improve their monotherapy activity.
Keywords: AKT inhibitor; biomarker; breast cancer; pharmacokinetics; phase 1
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1. Introduction
Precision medicine aims to identify patients based on distinct molecular profiles to provide optimal
and more effective treatments with reduced side effects. Breast cancer remains the most common
malignant disease in women worldwide [1], and despite improvements in outcome for early stages of
hormone receptor-positive (HR+) and HER2 negative breast cancer, advanced stages of the disease still
represent a high medical burden [2].
Alterations in the signaling pathways that regulate cellular survival and growth are a hallmark
of cancer [3]. Among these pathways, the PI3K/AKT/mTOR signaling cascade has been described as
frequently activated in different solid tumors, including up to 60% in breast cancers according to a
recent The Cancer Genome Atlas (TCGA) analysis [4]. The substitution of glutamic acid to lysine by a
somatic point mutation (E17K) renders the serine/threonine kinase AKT1 independent of upstream
PI3K signaling and leads to constitutive activation [5,6]. Within comprehensive molecular profiling
studies of breast cancer tissue, the AKT1E17K mutation was identified as a probable oncogenic driver
in patients, indicating that the inhibition of AKT1 presents a novel and specific drug target in this
disease [5,6]. However, as the prevalence of the AKT1E17K mutation was considered low (6.3%), a
patient selection strategy was necessary.
Several (pan-)AKT inhibitors have been developed recently [7]. These compounds are either
ATP-competitive (e.g., AZD5363 [8]) or allosteric (e.g., MK-2206 [9]) inhibitors and were investigated
in various indications. BAY 1125976 is an oral, small-molecule allosteric inhibitor of AKT1/2 with
high selectivity. It inhibits the proliferation of cells with PI3K/AKT/mTOR pathway alterations at
submicromolar IC50 values and showed its highest activity in luminal breast cancer cell lines. BAY
1125976 exhibited in vivo antitumor activity in preclinical breast cancer models after oral application [10].
Furthermore, a potent inhibition of the downstream signaling cascade was demonstrated by reduced
levels of p-AKT, p-PRAS40, p-S6RP, or p-70S6K, leading to antitumor efficacy in AKT1E17K-mutated
prostate and anal cancer models [10].
Here, we report the first-in-human phase I study that evaluated the safety, tolerability,
pharmacokinetics, and maximum tolerated dose (MTD) of BAY 1125976 in patients with advanced
solid tumors (NCT01915576). In an expansion phase, an enrichment strategy to identify patients with
AKT1E17K-mutated tumors was implemented. In addition, we will discuss options for further precision
medicine approaches in similar patient populations.
2. Results
2.1. Baseline Patient Demographics
A total of 79 patients were enrolled in this study (Table 1, Table S1). Twenty-nine patients received
the continuous once daily (QD) dose escalation schedule, while 22 patients were part of the twice daily
(BID) dose escalation. The breast cancer expansion cohort using 60 mg BID consisted of 28 patients and
was discontinued after the enrollment of eight patients with AKT1E17K mutation (Figure 1). Overall,
61 patients (77.2%) were female. The mean age of all the patients was 56.7 years (range 31–82 years).
Except for one patient in the 80 mg QD dose escalation and one patient in the 80 mg BID dose escalation,
all patients had a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0
(59.5%) or 1 (38.0%). Only one patient (40 mg BID cohort) did not receive any prior systemic anticancer
therapy. Sixty patients (75.9%) had prior radiotherapy. The baseline characteristics for patients with
AKT1E17K mutations were comparable to the whole study population.
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Table 1. Baseline patient demographics in the BAY 1125976 phase 1 study. BID: twice daily, ECOG: Eastern Cooperative Oncology Group, LSF: liquid service
formulation, QD: continuous once daily, WT: wild-type.
Parameter
10 mg LSF
QD
20 mg LSF
QD
40 mg
Tablet QD
80 mg
Tablet QD
120 mg
Tablet QD
40 mg
Tablet BID
60 mg
Tablet BID
80 mg
Tablet BID
60 mg Expansion
TotalTablet (BID)
WT AKT1E17K
N 3 3 4 13 6 3 15 4 19 9 79
Mean age, years (range) 53.3 (44–67) 49.7 (37–64) 59.0 (47–75) 61.2 (48–75) 53.5 (37–69) 66.3 (50–82) 55.1 (40–74) 56.3 (38–70) 55.3 (31–76) 57.3 (41–73) 56.7 (31–82)
Females, n (%) 2 (66.7) 2 (66.7) 2 (50.0) 10 (76.9) 4 (66.7) 2 (66.7) 8 (53.3) 3 (75.0) 19 (100.0) 9 (100.0) 61 (77.2)
ECOG performance status,
n (%)
0 0 1 (33.3) 2 (50.0) 7 (53.8) 2 (33.3) 2 (66.7) 10 (66.7) 2 (50.0) 14 (73.7) 7 (77.8) 47 (59.5)
1 3 (100.0) 2 (66.7) 2 (50.0) 5 (38.5) 4 (66.7) 1 (33.3) 5 (33.3) 1 (25.0) 5 (26.3) 2 (22.2) 30 (38.0)
2 0 0 0 1 (7.7) 0 0 0 1 (25.0) 0 0 2 (2.5)
Prior systemic anticancer
therapy, n (%) 3 (100.0) 3 (100.0) 4 (100.0) 13 (100.0) 6 (100.0) 2 (66.7) 15 (100.0) 4 (100.0) 19 (100.0) 9 (100.0) 78 (98.7)
Prior radiotherapy, n (%) 3 (100.0) 3 (100.0) 2 (50.0) 8 (61.5) 5 (83.3) 2 (66.7) 12 (80.0) 1 (25.0) 18 (94.7) 6 (66.7) 60 (75.9)
Patients with AKT1E17K mutation are also part of the 60 mg BID expansion cohort.
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2.2. Dose Escalation and Maximum Tolerated Dose 
During the initial QD dose escalation, no dose-limiting toxicity was observed until the 120 mg 
QD cohort. Here, two patients experienced Grade 3 or Grade 4 liver enzyme elevation of aspartate 
animotransferase (AST), alanine animotransferase (ALT), γ-glutamyltransferase (γ-GT), and one 
patient experienced Grade 3 elevation of alkaline phosphatase (AP). Based on PK and modeling data, 
a re-escalation using a BID schedule was initiated at 40 mg BID with the intent of maintaining target 
engagement whilst reducing Cmax under the hypothesis that higher Cmax may be linked to observed 
events. Two patients at the 80 mg BID dose level experienced Grade 3 liver enzyme elevation (AST, 
ALT), with one of these patients also showing Grade 3 hyperglycemia. Dose was then de-escalated 
to 60 mg BID and two patients experienced Grade 3 liver enzyme elevation (AST, ALT, γ-GT), too. 
The MTD estimate based on posterior dose-limiting toxicity (DLT) rates of the Bayesian dose 
response analysis was 81.1 mg for the QD schedule (with a coefficient of variation of 25.5%) and 65.1 
mg for the BID schedule (with a coefficient of variation of 38.1%), respectively. Therefore, the MTD 
and recommended dose for the expansion phase was selected as 60 mg BID. 
2.3. Safety 
During the study, 77 (97.5%) patients reported at least one treatment-emergent adverse event 
(TEAE), drug-related TEAEs were reported by 69 (87.3%) patients, and nine (11.4%) patients had 
TEAEs related to procedures required by the protocol. Eighteen (22.8%) patients had TEAEs that were 
Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or Grade 2, and 52 (65.8%) 
patients had TEAEs that were CTCAE Grade 3 or Grade 4, with overall only one patient in the 120 
mg QD cohort experiencing a Grade 4 increase of γ-GT. Most of the common Grade 3 drug-related 
TEAEs were increased ALT in 17 patients (21.5%), increased AST in 20 patients (25.3%), and increased 
AP in 27 patients (34.2%) (Table 2). Interestingly, only one patient experienced an on-target Grade 3 
hyperglycemia. Six patients died during the treatment period or within the 30 days safety follow-up 
window. All deaths were due to disease progression and considered not related to BAY 1125976. 
Serious adverse events (SAEs) were reported in 33 patients (41.8%). Six SAEs were considered to be 
drug-related. Forty-five (57.0%) patients had TEAEs leading to dose modification, and 22 (27.8%) 
patients had TEAEs leading to permanent discontinuation of the study drug. 
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Figure 1. Study outline and patient disposition during dose escalation steps and for the breast cancer
expansion cohort at 60 g BI B Y 1125976.
2.2. Dose Escalation and Maximum Tolerated Dose
During the initial QD dose escalation, no dose-limiting toxicity was observed until the 120 mg
QD cohort. Here, two patients experienced Grade 3 or Grade 4 liver enzyme elevation of aspartate
animotransferase (AST), alanine animotransferase (ALT), γ-glutamyltransferase (γ-GT), and one
patient experienced Grade 3 elevation of alkaline phosphatase (AP). Based on PK and modeling data,
a re-escalation using a BID schedule was initiated at 40 mg BID with the intent of maintaining target
engagement whilst reducing Cmax under the hypothesis that higher Cmax may be linked to observed
events. Two patients at the 80 mg BID dose level experienced Grade 3 liver enzyme elevation (AST,
ALT), with one of these patients also showing Grade 3 hyperglycemia. Dose was then de-escalated
to 60 mg BID and two patients experienced Grade 3 liver enzyme elevation (AST, ALT, γ-GT), too.
The MTD estimate based on posterior dose-limiting toxicity (DLT) rates of the Bayesian dose response
analysis was 81.1 mg for the QD schedule (with a coefficient of variation of 25.5%) and 65.1 mg for
the BID schedule (with a coefficient of variation of 38.1%), respectively. Therefore, the MTD and
recommended dose for the expansion phase was selected as 60 mg BID.
2.3. Safety
During the study, 77 (97.5%) patients reported at least one treatment-emergent adverse event
(TEAE), drug-related TEAEs were reported by 69 (87.3%) patients, and nine (11.4%) patients had
TEAEs related to procedures required by the protocol. Eighteen (22.8%) patients had TEAEs that
were Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or Grade 2, and 52 (65.8%)
patients had TEAEs that were CTCAE Grade 3 or Grade 4, with overall only one patient in the 120 mg
QD cohort experiencing a Grade 4 increase of γ-GT. Most of the common Grade 3 drug-related TEAEs
were increased ALT in 17 patients (21.5%), increased AST in 20 patients (25.3%), and increased AP
in 27 patients (34.2%) (Table 2). Interestingly, only one patient experienced an on-target Grade 3
hyperglycemia. Six patients died during the treatment period or within the 30 days safety follow-up
window. All deaths were due to disease progression and considered not related to BAY 1125976.
Serious adverse events (SAEs) were reported in 33 patients (41.8%). Six SAEs were considered to be
drug-related. Forty-five (57.0%) patients had TEAEs leading to dose modification, and 22 (27.8%)
patients had TEAEs leading to permanent discontinuation of the study drug.
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Table 2. BAY 1125976 related treatment-emergent adverse events occurring in ≥3 patients (Grade 3) or in ≥1 patient (Grade 4).
Adverse Events
10 mg LSF
QD
20 mg LSF
QD
40 mg
Tablet QD
80 mg
Tablet QD
120 mg
Tablet QD
40 mg
Tablet BID
60 mg
Tablet BID
80 mg
Tablet BID
60 mg Expansion Tablet (BID) Total
WT AKT1E17K
N 3 3 4 13 6 3 15 4 19 9 79
All, n (%)
Grade 3 - - 1 (25.0) 5 (38.5) 4 (66.7) 2 (66.7) 6 (40.0) 4 (100.0) 12 (61.1) 8 (88.9) 42 (53.2)
Grade 4 - - - - 1 (16.7) - - - - - 1 (1.3)
ALT increased, n (%)
Grade 3 - - - 2 (15.4) 2 (33.3) 1 (33.3) 2 (13.3) 3 (75.0) 4 (21.0) 3 (33.3) 17 (21.5)
AST increased, n (%)
Grade 3 - - - 2 (15.4) 3 (50.0) - 3 (20.0) 2 (50.0) 7 (36.8) 3 (33.3) 20 (25.3)
AP increased, n (%)
Grade 3 - - 1 (25.0) 3 (23.1) 2 (33.3) - 3 (20.0) 3 (75.0) 11 (57.9) 4 (44.4) 27 (34.2)
γ-GT increased, n (%)
Grade 3 - - - - - - 1 (6.7) - - - 1 (1.3)
Grade 4 - - - - 1 (16.7) - - - - - 1 (1.3)
Patients with AKT1E17K mutation are also part of the 60 mg BID expansion cohort.
Cancers 2019, 11, 1987 6 of 16
2.4. Pharmacokinetic Evaluation
BAY 1125976 was rapidly absorbed following continuous QD or BID oral administration of the
liquid service formulation (LSF) or the tablet formulation. Median time to reach tmax was in the range
of 0.5 to 3 h. Exposure was observed to increase with dose up to the 80 mg dose level in both schedules
(Figure 2, Table S2). The relative bioavailability assessment of BAY 1125976 (tablet versus LSF) at the
20 mg QD dose level and at the 40 mg QD dose level showed comparable Cmax and area under the
concentration time curve (AUC) values for both formulations (Table S3, Figure S1). The administration
of BAY 1125976 at the 80 mg QD dose level after a high-fat, high-calorie meal resulted in a reduction of
Cmax by 27% and an increase of AUC by 16% compared to administration under fasted conditions
(Table S4, Figure S1). There was a delay in absorption when the tablet was taken with food (median
tmax was 1 h and 4.1 h under fasted and fed conditions, respectively). Due to the small sample size in
the food effect cohort (n = 3), the data should be interpreted with caution.
a cers , , x FOR PEER REVIEW 1 f  
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Figure 2. Single and multiple dose area under the concentration time curve (AUC0-24h) of BAY 1125976
in the QD (A) and the BID (B) schedule, including patients at the 60 mg BID expansion cohort, showing
dose linearity for both schedules. C, cycle; D, day; Exp, expansion cohort.
2.5. Pharmacodynamic Biomarkers
To determine the degree of inhibition of the AKT signaling pathway by BAY 1125976, inhibition of
the phosphorylation of AKT and of its downstream target PRAS40 was determined in platelet-enriched
plasma samples after thrombin receptor-activating peptide (TRAP) stimulation (Figure 3). A transient
maximum inhibition of AKT phosphorylation was observed at 4 h post-treatment in both dosing
schedules (Figure 3A,B). While a decrease of p-AKT quickly returned to baseline in the QD schedule,
a sustained inhibition was observed for patients receiving BAY 1125976 in the BID schedule.
Similar data were obtained for the inhibition of phosphorylation of PRAS40 (Figure 3C,D). Overall,
a clear dose and exposure dependency of both p-AKT and p-PRAS40 inhibition was seen. PK/PD
(pharmacokinetic/pharmacodynamic) data demonstrated a suppression of more than 70% of p-AKT
and more than 30% of p-PRAS40 at the MTD dose level with an IC50 of approximately 5 µg/L for
p-AKT (Figure 3E,F). Although mandatory for patients in the expansion cohort, due to early disease
progression, some planned biopsies were not taken, and only 10 treatment biopsies were collected on
cycle 2, day 1. Of these, eight did not meet the prespecified quality criteria (e.g., relative tumor content).
Therefore, no further analyses of tissue-specific pharmacodynamic biomarkers were performed due to
the low number of evaluable cases.
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Figure 3. Inhibit on of phosphor tion of AKT (A,B) and PRAS40 (C,D) s pharmacodynamic
biomarkers in platelet-rich plasma (PRP) fr patients in the QD (left column) and BID (right column)
dose escalation parts in the BAY 1125976 Phase 1 study. PK/PD analysis on the suppression of p-AKT
(E) and p-PRAS40 (F) from thrombin receptor-activating peptide (TRAP)-stimulated platelets across
dose intervals relative to baseline (screening, C1D1 predose or C1D-3 predose). Values are normalized
to total AKT and total PRAS40, respectively. Vertical dotted line represents IC90 for p-AKT based on
clinical pharmacokinetic/pharmacodynamic (PK/PD) modeling. Arrows indicate when treatments were
started. C, cycle; D, day. PD: progressive disease.
2.6. AKT1E17K Status and Mutational Profiling
All patients with tumor AKT1E17K mutation enrolled in the study were identified based on prior
investigations at the different sites. All mutations were confirmed retrospectively using the Therascreen
assay. The de novo screening of a further 18 patients was not able to identify the AKT1E17K mutation,
which was in line with the expected low prevalence of the mutation.
Next-generation sequencing revealed dditional oncogenic mutatio s in the analyze samples
from the 60 mg BID breast cancer expansion cohort (n = 28). Onl samples from patients with efficacy
evaluation by Response Evaluation Criteria in Solid Tumors (RECIST) ere analyzed (n = 23), and
results were obtained for 14 patients. Other samples failed quality control or had too low tumor
content. The AKT1E17K mutation was not mutually exclusive to other known or potential oncogenic
drivers. The alterations identified in our study population also included other PI3K pathway members,
e.g., PIK3CA mutation, PTEN, or RICTOR, as well as e.g., TP53, BRCA1/2, KRAS, MYC, or FGFR1 and
FGFR2. Copy number alterations (CNAs) were observed in e.g., cell cycle control genes (CDKN2A/B,
Cancers 2019, 11, 1987 8 of 16
CDK6), fibroblast growth factor (FGF) signaling (FGF3, FGF4, FGF19), MDM2, or AURKA (Figure 4,
Figure S2). Overall, an average (min–max) of seven (3–12) mutations or CNAs with known or likely
oncogenic properties was detected per patient. Due to the low number of patients, no statistical
differences could be detected between patients with wild-type (WT) and AKT1E17K-mutated tumors.
Not surprisingly for our target population, alterations were most frequently found in ESR1 (estrogen
receptor α), PIK3CA, and TP53.
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Figure 4. Waterfall plot showing the best change (%) from baseline and response evaluation according to
RECIST v1.1 for patients from the 60 mg BID breast cancer expansio c hort (n = 28) in the BAY 1125976
phase 1 study. The AKT1E17K mutation status for each patient was detected from tumor specimen using
the Therascreen assay or based on pre-existing data determined at the investigational site. The table
depicts genetic aberrations with known or likely oncogenic properties in the target population as
found by next-generation sequencing (NGS) in tumor samples. # indicates the patient who had partial
response (−36.5% from baseline). PR, partial response; SD, stable disease; PD, progressive disease.
Color indications: Red, mutation; Green, copy number alteration (CNA); Blue, rearrangement; Gray, no
data available (failed analysis, low/no tumor content in sample or missing sample).
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2.7. Tumor Response Evaluation
Seventy-eight patients were evaluable for tumor response. The average number of prior lines of
therapy was 5.8 (range 0–14). No patient had a complete response, and one patient (1.3%) treated with
60 mg BID in the expansion cohort had a partial response as best response (−36.5% best change in
target lesions from baseline). Of the other overall 77 patients, 30 (38.5%) patients had stable disease, 38
(48.7%) patients had progressive disease, and data were missing for nine patients. At the 60 mg BID
expansion cohort (Figure 4), the above-mentioned one patient (3.6%) had a partial response, seven
patients (25.0%) had stable disease, and 15 patients (53.6%) had progressive disease (no data available
for five (17.9%) patients). Of the nine patients recruited into the study with the AKT1E17K mutation,
three (33.3%) patients had stable disease, three (33.3%) patients had progressive disease, and data were
missing for the other three patients. The overall median (95% confidence interval) time to disease
progression for the 78 evaluable patients was 38 (36, 43) days and 41 (22, 80) days for the nine patients
with the AKT1E17K mutation.
3. Discussion
Alterations of the PI3K/AKT/mTOR pathway belong to the most commonly found molecular
changes in human cancers, including breast cancer [4]. Early studies using inhibitors of PI3K
(phosphoinositide 3-kinase) (e.g., copanlisib [11], buparlisib [12] or alpelisib [13]) or downstream mTOR
(mammalian target of rapamycin) signaling complexes (e.g., temsirolimus [14,15] or everolimus [16,17])
in monotherapy indicate some clinical benefit in patients with advanced breast cancer. Therefore,
targeting the intermediate signaling step via the inhibition of AKT could be an additional way to inhibit
tumor cell growth, especially in cancers unresponsive to PI3K inhibitors. Activating mutations of the
AKT1 gene have been described in various solid tumors, including breast cancer [5]. The AKT1E17K point
mutation leads to the constitutive activation of the kinase in 6.3% of human breast cancer [6]. Although
this prevalence is rather low, novel sequencing and detection technologies, including next-generation
sequencing and respective biobanking approaches at clinical sites, identified a total of nine patients
with the AKT1E17K mutation for this phase 1 study. The further penetration of such technologies into
routine diagnostics will make even more rare alterations (e.g., NTRK gene fusions) attractive targets
for future drug development scenarios [18].
BAY 1125976 is a highly potent and oral specific allosteric inhibitor of AKT1/2 and demonstrated
antitumor activity in several preclinical cancer models, including breast cancer [10]. Therefore, this
phase 1 first-in-human study was initiated to determine the safety, tolerability, pharmacokinetics, and
MTD of BAY 1125976 in patients with advanced cancer.
The study started using a QD dose escalation scheme, and the occurrence of dose-limiting liver
toxicity as evidenced by the Grade 3 and Grade 4 elevation of transaminases, AP, or γ-GT at 120 mg led
to the identification of 80 mg as the MTD in the QD schedule. The observed hepatotoxicity is considered
to be a direct effect of prolonged inhibition of the PI3K/AKT/mTOR pathway in hepatocytes where it
regulates glucose homeostasis and other key metabolic pathways [19,20]. Preclinically, BAY 1125976
strongly reduced levels of p-AKT and p-PRAS40 after a single oral dose in tumor xenografts [10]. We
found a dose-dependent inhibition of both pharmacodynamic biomarkers with maximum inhibition
being detectable at 4 h post-dosing and a rapid return to baseline suggesting a rapid direct effect
link between AKT inhibition and biomarker modulation. This is in line with our preclinical data
that identified the inhibition of p-AKT and p-PRAS40 as pharmacodynamic biomarkers [10]. PK/PD
data demonstrated that the QD administration, even at the MTD, was not able to achieve sustained
coverage above the in vitro IC50 of p-AKT or p-PRAS40. Pharmacokinetic simulations of potential
other schedules predicted continuous IC50 coverage using a BID schedule. Therefore, this schedule
was initiated as an alternative dose escalation cohort starting at 40 mg BID. In this cohort, three
escalation steps up to 80 mg BID were performed, and Grade 3 liver toxicities were again identified as
dose-limiting. In line with the predictions, an assessment of p-AKT and p-PRAS40 confirmed sustained
inhibition with this schedule. The MTD was determined as 60 mg BID. Then, this dose level was used
Cancers 2019, 11, 1987 10 of 16
for further expansion in the breast cancer cohort. We observed uniform dose-limiting toxicities, i.e.,
liver enzyme elevations and hyperglycemia, which are in line with the expected mode of action of
AKT inhibitors [19,20].
Although ATP-competitive AKT inhibitors such as AZD5363 or GSK690693 have shown
encouraging preclinical results, this compound class shows significant clinical toxicity (hyperglycemia,
rash, liver toxicity) due to limited selectivity on ATP-binding site recognition in AKT proteins versus
other protein kinases [7,10,21]. To overcome these toxicities, allosteric AKT inhibitors such as MK-2206
or our compound BAY 1125976 were developed. Indeed, MK-2206 showed a significantly reduced rate
of Grade 3 hyperglycemia (3.0–9.3%) compared to the ATP-competitive AZD5363 (up to 39.0%) [22].
Compared to MK-2206, BAY 1125976 induced Grade 3 hyperglycemia only in one patient and also had
only one case of Grade 3 rash in a patient from the 60 mg BID dose escalation cohort, indicating a more
favorable tolerability, which might be due to the shorter half-life of BAY 1125976. Despite the strong
pharmacodynamic coverage as evidenced by observed biomarker modulation, BAY 1125976 was able
to induce a partial response in only one patient and stable disease in seven out of 28 patients treated in
the 60 mg BID expansion cohort. The disease control rate was 28.6%. Interestingly, patients harboring
the AKT1E17K mutation did not show signs of improved response over the general study population
with no partial responses and only three out of nine patients harboring the mutation with stable disease,
accounting for a disease control rate of 33.3%. Of the 14 patients with additional sequencing data
available, six patients (all with PD as the best response) had an additional PIK3CA mutation, while
other patients had mutations of FGFR signaling or cell cycle control genes such as CDKN2A (p16INK4)
that could counteract the effects of AKT inhibition by BAY 1125976.
Our results are in line with those from other AKT inhibitors used in monotherapy in clinical
trials [7]. The pan AKT inhibitor AZD5363 showed a similar pattern of target modulation with about
60% reduction in p-PRAS40 at 4 h and return to baseline within 24 h post-dosing and only limited
evidence of antitumor activity in a breast cancer expansion cohort as well [23]. The allosteric AKT
inhibitor MK-2206 showed only limited monotherapy activity against nasopharyngeal cancer [24],
biliary tract cancer [25], or gastric cancer [26]. For MK-2206, which has a long half-life of 60–80 h,
different dosing schedules were investigated, too. Both continuous QD and intermittent once weekly
dosing demonstrated a robust inhibition of p-AKT. While the once weekly schedule significantly
reduced treatment related side effects, it was not associated with sufficient clinical responses [27,28].
In our study, we were able to identify nine patients with the activating AKT1E17K point mutation
based on prior investigator knowledge. Although preclinical data indicate a high sensitivity of AKT1E17K
mutated tumor models to BAY 1125976 [10], these patients did not show signs of increased efficacy
compared to patients with AKT1 wild-type cancer. This is in contrast with the results from patients
with AKT1E17K alterations receiving AZD5363, who showed longer progression-free survival [29].
Additional genomic analyses in our study revealed that most patients harbored additional oncogenic
driver mutations. That means that AKT1E17K is not mutually exclusive to other alterations in the PI3K
signaling pathway, which is in line with recent findings on the genomic characterization of metastatic
HR+ breast cancer [23]. Higher sensitivity toward MK-2206 was hypothesized to be linked to additional
alterations in the PI3K pathway, e.g., the loss of PTEN or mutation or amplification of PIK3CA [24,30].
Similar results were also reported for AZD5363 [29], although exclusive PIK3CA mutations did not
correlate with increased response in another study in breast or gynecological cancer patients where
concurrent mutations in KRAS, NRAS, HRAS, or BRAF were excluded [23]. Interestingly, patients
with an allelic imbalance in AKT1E17K showed longer progression-free survival (PFS), while patients
with subclonal mutations showed rapid disease progression in this study [29]. In our study, the best
response was observed in an AKT1 wild-type breast cancer patient who had an upstream PIK3CA
mutation, which is in line with the finding of coincident PI3KCA mutations and improved PFS from
another study [29]. In this study, patients with hotspot mutations in the ligand-binding domain of
estrogen receptor α (ESR1) showed a shorter PFS. Next-generation sequencing (NGS) data from our
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study revealed that eight out of 14 evaluable patients also had mutations in ESR1, which could explain
the overall disappointing efficacy.
Although overall the number of cases is small, data from our study and from the literature
indicate that selecting patients based on AKT1E17K mutation alone is not sufficient to identify potential
responders to such treatment. In a direct comparison, MK-2206 proved to be inferior to everolimus
in renal cell cancer [31]. Combination approaches that include PI3K pathway inhibitors such as
everolimus [32], buparlisib [33], or alpelisib [13,34,35] have shown promising results also in breast
cancer patients, and additional preclinical data also confirm the combination potential for AKT
inhibitors [36]. While a recent phase 2 study using MK-2206 and anastrozole in PIK3CA-mutant
ER-positive breast cancer did not show additive efficacy [37], alpelisib in combination with fulvestrant
received FDA approval for the treatment of patients with PIK3CA-mutated HR+ advanced breast
cancer after previous endocrine therapy (PFS 11.0 versus 5.7 months) and also showed a treatment
benefit in patients without PIK3CA mutation compared to placebo control (overall response rate 26.6%
versus 12.8%) [38].
4. Materials and Methods
The study was approved by the respective independent ethics committees and institutional review
boards for each study site (NCT Heidelberg: AFmu-327/2013; Kantonsspital St. Gallen: EKSG 13/064 /
SG 355/13; Institut Gustave Roussy: 2012-004671-39 CPP 3099; MD Anderson Cancer Center: 2013-0727;
Washington University School of Medicine: 201311119; UCLA: 13-001234), and it was conducted in
accordance with the Declaration of Helsinki and Good Clinical Practice. All patients provided written
informed consent before study participation.
4.1. Study Design
The study was a multi-center, open-label, non-randomized, phase I dose escalation study in
patients with advanced solid tumors (NCT01915576). BAY 1125976 was applied orally in 21-day cycles.
The primary objective was to determine the safety, tolerability, pharmacokinetics, and MTD in either
continuous once daily (QD) or continuous twice daily (BID) dosing. Secondary objectives included
assessment of pharmacokinetics (food effect), pharmacodynamic parameters, and tumor response.
Furthermore, one of the objectives was to explore whether patients with tumor AKT1E17K mutation
show an improved clinical benefit rate (partial response [PR] + stable disease [SD]) compared to
patients without this tumor mutation. The study consisted of five dose escalation cohorts in the QD
schedule and three dose escalation cohorts in the BID schedule. The expansion cohort at the BID MTD
aimed to enrich for at least eight patients with an AKT1E17K mutation in a population of advanced,
metastatic, or refractory solid tumors or HR+ metastatic breast cancer (Figure 1).
4.2. Treatment
BAY 1125976 was administered orally at a starting dose of 10 mg QD as a water-based liquid
service formulation (LSF; 5 mg/mL), then changing to a tablet formulation at a dose of 40 mg QD.
A bridging cohort compared the relative bioavailability of these two formulations. Dose escalation
steps were 10 mg, 20 mg, 40 mg, 80 mg, and 120 mg QD. The BID dose escalation was initiated at 40 mg
BID using the tablet formulation after the completion of the QD schedule and continued with 60 mg
and 80 mg BID. The relative bioavailability of LSF versus the tablet was assessed on cycle 1, day −3
(3 days before the start of cycle 1) in the 20 mg and the 40 mg QD cohort. The effect of a high-fat meal
on the PK of BAY 1125976 was assessed at the QD MTD after the administration of BAY 1125976 tablets
immediately following consumption of a high-fat, high-calorie meal on cycle 1, day −3.
A dose-limiting toxicity (DLT) was defined as the occurrence of any of the following attributed to
BAY 1125976 during cycle 1 of each dose level: absolute neutrophil count <0.5 × 109/L for ≥7 days;
febrile neutropenia with absolute neutrophil count <0.5× 109/L and a single body temperature >38.3 ◦C
or a sustained temperature ≥38.0 ◦C for more than 1 h; platelets <25 × 109/L; persistent hematological
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toxicity ≥ Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 for >7 days; any
CTCAE Grade 3 or Grade 4 non-hematological toxicity related to study drug (excluding alopecia,
nausea, and vomiting, not refractory to anti-emetics).
Dose escalation would not continue if the MTD had been defined with good precision according
to model-based predictions using the continuous reassessment method or if the selected dose level
for the next cohort had already been given in nine patients. Patients were treated until disease
progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion
of the investigator.
4.3. Inclusion Criteria
Patient were eligible if they were 18 years or older and had any kind of advanced, metastatic,
or refractory solid tumors not amenable for standard therapy for the dose escalation parts and had
histologically or cytologically proven HR+ metastatic breast cancer that was refractory to standard
therapy and not amenable to curative surgery for the expansion part. At least eight patients with
proven AKT1E17K mutation were planned to be included in the expansion part. Patients had to have
evaluable and measurable disease according to the Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1 and an Eastern Cooperative Oncology Group (ECOG) performance status of 0
to 2. Adequate bone marrow, liver, and renal functions were assessed by laboratory methods within
7 days before starting study treatment. All patients had to provide a tumor biopsy (either a new
on study biopsy or an archival sample not older than 6 months) before treatment start. A second
(paired) on-treatment biopsy on cycle 2, day 1 was mandatory for patients in the MTD cohort of the
QD schedule for further pharmacodynamic biomarker analyses.
4.4. Safety, Response, and Pharmacokinetics Assessments
Safety evaluations included adverse events (AEs), vital signs, laboratory tests, and 12-lead
electrocardiograms at screening, at planned times during each cycle, during follow-up, and up to
30 days after the last dose. Adverse events were graded using the National Cancer Institute Common
CTCAE version 4.03. All patients receiving at least one dose of BAY 1125976 were included in the
safety analysis set.
Investigators assessed tumor response according to RECIST v1.1 every two cycles. Pharmacokinetic
assessments of single-dose and multiple-dose BAY 1125976 were planned in all patients in the dose
escalation arms (single-dose in QD only), and in at least six patients at the MTD. Data were calculated
using non-compartmental methods to estimate maximum drug concentration (Cmax) and area under
the concentration time curve (AUC). The relative bioavailability of LSF and tablet were compared in
the 20 and 40 mg cohorts of the QD dose escalation. The effect of food on compound exposure was
compared in the 80 mg cohort.
4.5. Biomarker Assessments
A tumor biopsy was mandatory at screening (freshly taken or not older than six months) for all
subjects. A pre-screening biopsy was mandatory for patients enrolled in the MTD expansion part
of the study unless the AKT1E17K mutation status was confirmed previously. Otherwise, AKT1E17K
mutations were investigated from fresh or archival biopsy samples using the Qiagen Therascreen
AKT1 RGQ PCR Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. From
new study biopsies, additional mutational profiling was performed by next-generation sequencing
using FoundationOne® T5a panel (Foundation Medicine, Cambridge, MA, USA).
Blood-based biomarker analyses were measured in platelet-rich plasma (PRP) to assess changes in
the pharmacodynamics of the AKT pathway as phospho-AKT (p-AKT), total AKT, phosphor-PRAS40
(p-PRAS40) and total PRAS40. Briefly, 10 mL blood was collected with a S-Monovette® Citrate
(Sarstedt, Nümbrecht, Germany) using a 21G needle. After inverting the tube 8–10 times, samples were
centrifuged at 400 g at room temperature for 4 min without brake. The upper PRP phase was separated
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into two vials and thrombin receptor-activating peptide (TRAP) or a control solution was added
followed by incubation at 37 ◦C for 10 min in a thermoblock without shaking. After centrifugation of
both samples at 800 g and +4 ◦C for 3 min, supernatant was discarded, and cells were lysed by adding
completed lysis-buffer before cells were frozen at −70 ◦C in a precooled CoolSafe Chamber. Batched
analysis using Mesoscale Discovery multiplex assays was performed (Nuvisan, Ulm, Germany).
4.6. PK/PD analysis
The pharmacokinetic/pharmacodynamic link between BAY 1125976 and the biomarkers p-AKT and
p-PRAS40 was observed to show no evidence of hysteresis, and therefore was examined using nonlinear
regression between plasma concentration and corresponding biomarker response in GraphPad Prism 7
(GraphPad Software Inc., La Jolla, CA, USA).
4.7. Statistical Analysis
Descriptive statistics were used to summarize demographic data, other baseline characteristics,
AEs, safety parameters, and tumor assessment data. All subjects who received at least one dose of BAY
1125976 were included in the safety evaluation. All subjects who completed Cycle 1 with at least 80% of
the required BAY 1125976 dose or discontinued during Cycle 1 due to a DLT were included in the MTD
evaluation. All subjects who received at least one dose of BAY 1125976 and who have post-baseline
efficacy data available were included in the efficacy evaluations. All subjects who completed the study
were included in the evaluation of PD/PK. The incidence of subjects with DLTs during Cycle 1 was
summarized by treatment and dose and modeled as a function of BAY 1125976 dose using Bayesian
logistic regression. The incidence of treatment-emergent adverse events and drug-related adverse
events, respectively, was summarized by treatment in frequency tables using the CTCAE grade.
5. Conclusions
In summary, our findings and data from the literature show that deeper genetic analyses and a
thorough understanding of the underlying biological dependencies are necessary to clearly identify
further pathway alterations that may positively or negatively impact on sensitivity toward AKT1
inhibition in monotherapy [7,39]. Taken holistically, these data suggest that AKT1 inhibition may
remain an attractive target; however, an overarching appreciation for the presence of other oncogenic
drivers and rigorous patient selection is likely necessary to markedly increase the probability of AKT1
inhibition becoming associated with robust efficacy.
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